1-4 of 4
Mark Hertzberg, MBBS, PhD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

The T-Cell Receptor Repertoire Predicts Interim-PET in Patients with DLBCL Treated with R-CHOP: An Observational Study from a Prospective Clinical Trial

Mohamed Shanavas, MD, Mark Hertzberg, MBBS, PhD, Rodney J Hicks, MD, John F Seymour, MBBS, PhD, Joshua W.D. Tobin, MD, Marina Mathews, PhD, Santiyagu Francis, PhD, Frank Vari, PhD, Maher K Gandhi, MB, FRACP, FRCPath, PhD, Colm Keane, MB, PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 825.
https://doi.org/10.1182/blood.V130.Suppl_1.825.825
Published: 2017
Journal Articles

Addition of Polatuzumab Vedotin to Bendamustine and Rituximab (BR) Improves Outcomes in Transplant-Ineligible Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Versus BR Alone: Results from a Randomized Phase 2 Study

Laurie H. Sehn, MDMPH, Alex F. Herrera, MD, Matthew J. Matasar, MD, Manali Kamdar, Andrew K. McMillan, FRCP, Tae Min Kim, Won Seog Kim, MD, Ph. D., Mark Hertzberg, MBBS, PhD, Muhit Ozcan, MD, Elicia Penuel, Ji Cheng, Jamie M. Hirata, Grace Ku, Christopher Flowers, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 2821.
https://doi.org/10.1182/blood.V130.Suppl_1.2821.2821
Published: 2017
Journal Articles

Differences in Quality of Life Between Bendamustine Plus Rituximab Compared with Standard First-Line Treatments in Patients with Previously Untreated Advanced Indolent Non-Hodgkin's Lymphoma or Mantle Cell Lymphoma

John M. Burke, MD, Richard H. Van der Jagt, MD, Brad S. Kahl, M.D., Peter Wood, MRCP, Tim E. Hawkins, MBChB, David MacDonald, MD, FRCPC, Mark Hertzberg, MBBS, PhD, Yiu-Lam Kwan, MBBS, David Simpson, MBChB, Michael Craig, MD, Kathryn Kolibaba, MD, Samar Issa, MBChB, FRACP, FRCPA, Richard E. White, PhD, MPH, MBE, Mihaela C. Munteanu, MS, Regina Clementi, RN, MS, Ling Chen, PhD, Ian W. Flinn, MD, PhD
Journal: Blood
Blood (2012) 120 (21): 155.
https://doi.org/10.1182/blood.V120.21.155.155
Published: 2012
Journal Articles

An Open-Label, Randomized Study of Bendamustine and Rituximab (BR) Compared with Rituximab, Cyclophosphamide, Vincristine, and Prednisone (R-CVP) or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in First-Line Treatment of Patients with Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL): The Bright Study

Ian W. Flinn, MD, PhD, Richard H. Van der Jagt, MD, Brad S. Kahl, M.D., Peter Wood, MRCP, Tim E. Hawkins, MBChB, David MacDonald, MD, FRCPC, Mark Hertzberg, MBBS, PhD, Yiu-Lam Kwan, MBBS, David Simpson, MBChB, Michael Craig, MD, Kathryn Kolibaba, MD, Samar Issa, MBChB, FRACP, FRCPA, Mihaela C. Munteanu, MS, Regina Clementi, RN, MS, Ling Chen, PhD, John M. Burke, MD
Journal: Blood
Blood (2012) 120 (21): 902.
https://doi.org/10.1182/blood.V120.21.902.902
Published: 2012